KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Diluted Average) (2023 - 2025)

Biocryst Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $218.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 5.75% year-over-year to $218.6 million; the TTM value through Dec 2025 reached $218.6 million, up 5.75%, while the annual FY2025 figure was $218.6 million, 5.75% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $218.6 million in Q4 2025 per BCRX's latest filing, roughly flat from $218.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $218.6 million in Q4 2025 to a low of $192.2 million in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $209.7 million, with a median of $206.7 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 7.54% in 2024, then rose 4.46% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $192.2 million in 2023, then rose by 7.54% to $206.7 million in 2024, then grew by 5.75% to $218.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Shares Outstanding (Diluted Average) are $218.6 million (Q4 2025), $218.3 million (Q3 2025), and $217.6 million (Q2 2025).